Biosimilar Testing and Development Services Market

Market Overview The Global Biosimilar Testing and Development Services Market is poised for substantial growth, projected to increase from USD 3.73 Billion in 2025 to USD 7.53 Billion by 2031, demonstrating a robust 12.42% Compound Annual Growth Rate. These services involve specialized analytical, bioanalytical, and clinical activities outsourced by pharmaceutical companies to verify the safety, efficacy, and structural similarity of biosimilars compared to their reference biologics. A primary catalyst for this expansion is the impending patent expiration of numerous blockbuster biologics, which fuels an escalating demand for cost-effective therapeutic alternatives within global healthcare systems. This "patent cliff" compels biopharmaceutical developers to aggressively pursue biosimilar creation to capture market share, necessitating comprehensive analytical characterization and extensive clinical trials to meet complex regulatory requirements, as evidenced by the FDA's approval of a record 18 biosimilars in 2024. Furthermore, the increasing trend of outsourcing biosimilar development activities allows pharmaceutical firms to strategically leverage external expertise from contract research and manufacturing organizations, accessing advanced infrastructure without incurring heavy capital costs. This approach not only mitigates risks and streamlines development but also allows companies to focus internal resources on commercialization, as reflected by an 11.7% revenue growth in non-COVID late-phase and commercial manufacturing for a major CDMO and the significant market share achieved by adalimumab biosimilars in the U.S. Market Driver Expiration of patents for major blockbuster biologics serves as the fundamental catalyst expanding the Global Biosimilar Testing and Development Services Market. As exclusive rights for high-revenue biologics conclude, biopharmaceutical developers aggressively pursue the creation of biosimilar alternatives to capture market share, necessitating comprehensive analytical characterization and clinical trials to demonstrate biosimilarity. This "patent cliff" creates an immediate surge in demand for specialized testing services to navigate regulatory requirements for new approvals, as developers must prove their molecules are highly similar to the reference product. According to the U.S. Food and Drug Administration, January 2025, in the '2024 New Drug Therapy Approvals Annual Report', the agency approved 18 biosimilars in 2024, a record number that underscores the intensifying volume of molecules requiring rigorous validation and development support. Growth in outsourcing of biosimilar development activities allows pharmaceutical companies to leverage external expertise for complex analytical and clinical requirements, further driving market revenue. Biopharmaceutical firms are increasingly partnering with contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) to access advanced infrastructure without incurring the heavy capital costs associated with internal facility expansion. This strategic shift mitigates risks and focuses internal resources on commercialization while external partners manage the intricate bioanalytical testing phases. According to WuXi Biologics, August 2024, in the 'Interim Report 2024', revenue from non-COVID late-phase and commercial manufacturing grew by 11.7%, reflecting this sustained industry reliance on external development partners. The success of this outsourced model is evident in the commercial uptake of these rigorously tested products; according to Samsung Bioepis, October 2024, in the 'Fourth Quarter 2024 US Biosimilar Market Report', the market share for adalimumab biosimilars reached 22% in the U.S. by August 2024. Market Challenge Rigorous and divergent regulatory standards across different jurisdictions constitute a formidable barrier restricting the scalability of the Global Biosimilar Testing and Development Services Market. While pharmaceutical developers outsource to experts to navigate approval pathways, the lack of global harmonization necessitates extensive and duplicative analytical and clinical comparative studies to satisfy differing regional requirements. This regulatory fragmentation forces contract research organizations and developers to execute redundant testing protocols for the same molecule, significantly inflating development costs and extending timelines. These financial and operational burdens act as a deterrent, discouraging pharmaceutical companies from initiating new biosimilar programs and directly reducing the volume of projects entering the outsourcing pipeline. The direct impact of these regulatory hurdles is a constricted development funnel, which effectively caps the potential revenue stream for testing and development services. High entry barriers prevent many potential biosimilars from ever reaching the clinical phase, thereby stalling demand for bioanalytical support. According to the Association for Accessible Medicines, in 2024, more than 80 percent of brand biologics that are eligible for competition did not have a biosimilar candidate in the development pipeline. This statistic underscores how regulatory complexity and the associated resource intensity directly suppress market activity, limiting the demand for outsourced services despite the broader sector's theoretical potential. Market Trends The Adoption of Pharmacodynamic Biomarkers to Waive Comparative Efficacy Trials represents a fundamental regulatory paradigm shift designed to reduce the high capital barriers associated with biosimilar development. By validating biosimilarity through advanced analytical characterization and pharmacokinetic/pharmacodynamic (PK/PD) data rather than large-scale Phase 3 studies, regulatory bodies are enabling a more streamlined and cost-efficient approval process. This shift allows developers to reallocate resources from redundant clinical testing to manufacturing and portfolio expansion, significantly lowering the threshold for market entry. According to MedPath, September 2025, in the article 'FDA Grants First-Ever Waiver of Clinical Efficacy Studies for Monoclonal Antibody Biosimilars', the FDA’s decision to waive these clinical efficacy requirements is expected to reduce the cost of developing biosimilars by more than 90%. Integration of Artificial Intelligence and Machine Learning in Comparability Studies is transforming the analytical phase of biosimilar development by enhancing the precision and speed of structural characterization. AI algorithms are increasingly employed to predict molecular behavior, optimize cell line development, and analyze vast datasets to demonstrate structural similarity to reference biologics with unprecedented accuracy. This technological integration not only accelerates the identification of critical quality attributes but also mitigates the risk of failure in later development stages by ensuring higher fidelity in early comparability assessments. According to Pharmaphorum, January 2025, in the article 'Biopharma's AI rally: Readiness not hype in 2025', 67% of large biopharma companies have adopted artificial intelligence and machine learning technologies to drive operational efficiency and accelerate discovery pipelines. Key Market Players * Thermo Fisher Scientific Inc. * Charles River Laboratories, Inc. * SGS S.A. * Eurofins Scientific Limited * Intertek Group plc * Element Materials Technology * Pacific BioLabs, Inc. * Sartorius AG * WuXi AppTec * Syngene International Ltd. Report Scope In this report, the Global Biosimilar Testing and Development Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Biosimilar Testing and Development Services Market, By Service Type * Analytical Testing * Clinical Testing # Biosimilar Testing and Development Services Market, By Molecule Type * Monoclonal Antibodies * Recombinant Hormones * Insulin * Interferons * Enzymes * Others # Biosimilar Testing and Development Services Market, By Therapeutic Area * Oncology * Autoimmune Diseases * Diabetes * Infectious Diseases * Neurology * Others # Biosimilar Testing and Development Services Market, By End User * Pharmaceutical & Biotechnology Companies * Contract Research Organizations * Academic & Research Institutes * Others # Biosimilar Testing and Development Services Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Biosimilar Testing and Development Services Market. Available Customizations: Global Biosimilar Testing and Development Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).